Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Notification under AIM Rule Schedule Two (g)

9 Oct 2013 08:48

RNS Number : 0827Q
Allergy Therapeutics PLC
09 October 2013
 



9 October 2013

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Notification under AIM Rule Schedule Two (g)

 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, makes the following update announcement under AIM Rule Schedule Two (g) regarding Stephen Smith, a non-executive director of Allergy Therapeutics plc.

 

In addition to being a non-executive director of the Company, Stephen Smith acts as a 'company doctor' working with companies in distressed situations and in some cases the role has required a restructuring through a pre-planned administration/receivership or a planned insolvency to ensure an orderly winding down of the business. In providing these services, Stephen Smith was appointed as a director of the companies listed below in Table 1 which had administrators, receivers or liquidators appointed. These companies were part of the following groups:

 

· Texon International Group where Stephen Smith was appointed a director in 2004 and subsequently there was a restructuring in 2005 through a receivership which created a viable group where he continues to be a director.

 

· Ethel Austin Group where Stephen Smith was appointed a director in 2005. In 2008 lenders sold their secured loans to a company which appointed administrators a few days later.

 

· The Food & Drink Group where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 in a pre-planned process to achieve a sale of the profitable parts of the business.

 

· Paramount Restaurants Group where Stephen Smith was appointed a director in 2011 and later that year arranged a restructuring and subsequent pre-planned administration to achieve disposals of the profitable parts of the group.

 

· Ennstone plc where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 to complete a restructuring which ensured the viability of the UK and European businesses and protected the US business via a Chapter 11 process.

 

Table 1

 

Company

Comments

ACLM Limited (in administration)

Part of Ethel Austin Group

Bluelodge Limited (in administration)

Part of The Food & Drink Group

Burlington Restaurant Limited (in administration)

Part of The Food & Drink Group

Ennstone plc (in administration)

Holding company

Enterprises Realisations Limited (in administration)

Part of The Food & Drink Group

Ethel Austin Retail Group Limited (in administration)

Part of Ethel Austin Group

Ethel Austin Retail Holdings Limited (in administration)

Part of Ethel Austin Group

Futurestar Limited (in administration)

Part of The Food & Drink Group

Group Realisations Limited (in administration)

Part of The Food & Drink Group

Hartford Operations Limited (in administration)

Part of The Food & Drink Group

J Bar Limited (in administration)

Part of The Food & Drink Group

Montana plc (in administration)

Part of The Food & Drink Group

Newtaste Restaurants Limited (in administration)

Part of The Food & Drink Group

Noteframe Limited (in administration)

Part of Ethel Austin Group

Noxet Administration Services Limited

Part of Texon International group

PWC Realisations Limited (in administration)

Part of The Food & Drink Group

Texon Group Limited

Part of Texon International group

Texon Holdings Ltd (in liquidation)

Part of Texon International group

Texon International Limited

Part of Texon International group

The Food & Drink Group plc (in administration)

Part of The Food & Drink Group

USM (Holdings) Ltd

Part of Texon International group

Vantis Financial Management Limited (in administration)

Part of Vantis group

Vantis plc (in administration)

Part of Vantis group

Caffe Uno Brasseries Limited (in administration)

Part of Paramount Restaurants group

Charlotte Street Restaurants Limited

Part of Paramount Restaurants group

Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Craftbutton Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Leviathan Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Acquisitions Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Holdings Limited (in administration)

Part of Paramount Restaurants group

Paramount Limited (in administration)

Part of Paramount Restaurants group

Paramount Restaurants Limited (in administration)

Part of Paramount Restaurants group

Smile Restaurants Limited (in liquidation)

Part of Paramount Restaurants group

 

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 821

Ian Postlethwaite

Finance Director

Manuel Llobet

Chief Executive Officer

www.allergytherapeutics.com

Peel Hunt LLP

+44 (0) 20 7418 8900

James Steel / Dr. Vijay Barathan

FTI Consulting

+44 (0) 207 831 3113

Simon Conway / Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSDIRLAIIV
Date   Source Headline
31st Mar 20267:00 amRNSInterim Results for six months ended 31 Dec 2025
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
4th Mar 20267:00 amRNSPositive Biomarker Results from PROTECT Trial
26th Feb 20267:00 amRNS-RAllergy Therapeutics presents progress at AAAAI
23rd Feb 20267:51 amRNSUpdate on funding and total voting rights
30th Jan 20268:22 amRNSChief Strategy Officer and Board appointments
29th Jan 20262:13 pmRNSResult of Annual General Meeting
28th Jan 20264:48 pmRNSGrant of Options under Long Term Incentive Scheme
19th Jan 20267:00 amRNSHalf Year Trading Update
6th Jan 20267:00 amRNSNotice of 2025 Annual General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
16th Dec 20257:00 amRNSGrassmuno® marketing authorisation in Germany
12th Dec 20257:00 amRNSAuthority for allotment of New Shares
11th Dec 20257:00 amRNSPrelim Results and publication of Annual Report
9th Dec 20257:00 amRNSPrimary Safety Endpoint Met in PROTECT trial
6th Nov 20257:22 amRNSCompany to Evaluate Dual Listing on HKEX
30th Oct 20257:00 amRNSG308 Phase III Year 2 Patient Screening Starts
29th Oct 20257:00 amRNSWarrant Exercise and Paydown of Debt
16th Oct 20257:00 amRNSFurther progress in Phase I/IIa PROTECT trial
31st Jul 20257:00 amRNS-RGrass MATA MPL Publications in Allergy Journal
21st Jul 20257:00 amRNSTrading update for the year ended 30 June 2025
11th Jul 20257:00 amRNSPDMR Dealings
13th Jun 20257:00 amRNS-RAllergy Therapeutics presents findings at EAACI
10th Jun 20257:04 amRNS-REAACI Early Career Research Award
31st Mar 20257:00 amRNSInterim Results for six months ended 31 Dec 2024
27th Mar 20257:00 amRNSAdvancement to final phase of PROTECT trial
3rd Mar 20257:00 amRNSNew Executive Long Term Incentive Awards
27th Feb 20257:00 amRNS-RPresentations at 2025 AAAAI / WAO Joint Congress
17th Feb 20257:00 amRNSGrass MATA MPL Phase III data published in Allergy
14th Feb 20257:00 amRNSGrant of Options
28th Jan 20257:00 amRNSHalf Year Trading update
22nd Jan 20257:00 amRNSPDMR Dealing and Total Voting Rights
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20241:41 pmRNSExercise of Options and Total Voting Rights
17th Dec 20244:19 pmRNSBlock Listing Interim Review
16th Dec 20243:33 pmRNSResult of Annual General Meeting
4th Dec 20247:00 amRNSPositive Interim Data from PROTECT Trial
27th Nov 20247:00 amRNSFirst Patient Dosed in G308 Paediatric Trial
25th Nov 20247:00 amRNSSubmission of MAA for Grass MATA MPL
21st Nov 20247:00 amRNSNotice of 2024 Annual General Meeting
6th Nov 20247:00 amRNSAudited Preliminary Results 2024
21st Oct 20247:00 amRNSCommencement of Phase III Paediatric Trial
16th Oct 20247:00 amRNSUpdate on funding
1st Oct 20247:00 amRNSUpdate on funding and preliminary results
17th Sep 20247:00 amRNSProgression of patient cohorts in PROTECT Trial
27th Aug 20247:00 amRNSUpdate on funding
22nd Jul 20247:01 amRNSTrading update for the year ended 30 June 2024
22nd Jul 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.